SignalCorporate
Prestige Consumer Healthcare (PBH) Stock May Be Undervalued Despite Lowered Revenue Guidance
Prestige Consumer Healthcare stock may be undervalued despite lowered revenue guidance.
Context
What happened: Prestige Consumer Healthcare ($PBH) shares are down sharply this year, and coverage questions whether the current price is supported by earnings after management trimmed revenue and EPS guidance.
Key numbers: Share price US$48.00, down 21.6% year to date. P/E 14.7x versus Pharmaceuticals industry average 17.1x and peer group average 19.9x.
Why it matters: The guidance cut stems from supply constraints in the Clear Eyes product line, which the content says can affect views on the reliability of cash generation. The P/E discount persists even after expectations were reset.
Market: +3.9% today ($48.00), -21.6% YTD, 0.8x vol — as of 23:47 UTC
What changed
Prestige Consumer Healthcare ($PBH) shares are down sharply this year, and coverage questions whether the current price is supported by earnings after management trimmed revenue and EPS guidance.
Why it matters
The guidance cut stems from supply constraints in the Clear Eyes product line, which the content says can affect views on the reliability of cash generation. The P/E discount persists even after expectations were reset.
Market: +3.9% today ($48.00), -21.6% YTD, 0.8x vol — as of 23:47 UTC